Lombard Medical (OTCMKTS:EVARF) versus PAVmed (NASDAQ:PAVM) Financial Comparison

Lombard Medical (OTCMKTS:EVARF) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Lombard Medical and PAVmed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lombard Medical	N/A	N/A	N/A	N/A	N/A
PAVmed	$1.99 million	5.92	-$64.18 million	$0.71	0.97

Lombard Medical has higher earnings, but lower revenue than PAVmed.

Profitability

This table compares Lombard Medical and PAVmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lombard Medical	N/A	N/A	N/A
PAVmed	602.97%	N/A	-92.36%

Analyst Recommendations

This is a summary of recent ratings for Lombard Medical and PAVmed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lombard Medical	0	0	0	0	0.00
PAVmed	0	0	1	0	3.00

PAVmed has a consensus target price of $19.00, suggesting a potential upside of 2,653.62%. Given PAVmed’s stronger consensus rating and higher possible upside, analysts clearly believe PAVmed is more favorable than Lombard Medical.

Insider & Institutional Ownership

19.9% of PAVmed shares are owned by institutional investors. 7.3% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

PAVmed beats Lombard Medical on 7 of the 8 factors compared between the two stocks.

About Lombard Medical

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.